Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

Synthetic DNA Start-Up Raises $13M in Early Funds

A company producing synthesized DNA for medical and other biotechnology applications is raising €11 million ($US 13 million) in its first venture funding round. . . . → Read More: Synthetic DNA Start-Up Raises $13M in Early Funds

Trial Shows Antibody Effective Against Asthma

Results from a large-scale clinical trial show a synthetic antibody, when added to standard treatments, reduces asthma attacks and improves lung functioning. . . . → Read More: Trial Shows Antibody Effective Against Asthma

Start-Up Lands $10M for Gene-Editing HIV Treatments

A new enterprise developing treatments using gene editing to eliminate HIV infections received $10 million in its seed funding round. . . . → Read More: Start-Up Lands $10M for Gene-Editing HIV Treatments

Field Tests of Genetically Modified Moths to Begin

Outdoor tests of a genetically engineered diamondback moth, a difficult agricultural pest, altered to stop reproducing and collapse the species, are about to get underway. . . . → Read More: Field Tests of Genetically Modified Moths to Begin

Engineered T-Cell Trials Stopped after Patient Death

The Food and Drug Administration stopped two clinical trials testing genetically engineered T-cells from the immune system to treat leukemia, after a participant in one trial died. . . . → Read More: Engineered T-Cell Trials Stopped after Patient Death

Trial Underway Testing Alzheimer’s-Schizophrenia Drug

A new clinical trial began in the U.K. in a test of an experimental drug to treat schizophrenia associated with Alzheimer’s disease. . . . → Read More: Trial Underway Testing Alzheimer’s-Schizophrenia Drug

Simple Cell Programming Designed for Gene Therapies

A simpler technique using nanoscale particles was shown in lab tests to deliver messenger RNA to reprogram cells for gene therapies, including changes in T-cells in the immune system now approved to treat a type of leukemia. . . . → Read More: Simple Cell Programming Designed for Gene Therapies

Engineered T-Cell Company Acquired for $11.9 Billion

A company developing personal cancer therapies that genetically engineer a patient’s immune system cells is being acquired in a deal valued at $11.9 billion. . . . → Read More: Engineered T-Cell Company Acquired for $11.9 Billion

Forensic Genomics Company Spun-Off From Illumina

A new company is being established to provide genomics analysis systems for law enforcement, spun-off from a leading maker of genomics systems. . . . → Read More: Forensic Genomics Company Spun-Off From Illumina

Engineered Insulin-Producing Cells to Be Grown in Lab

A team from three universities is developing in the lab synthetic islet cells, the cells that produce insulin in the pancreas, for eventual transplantation in people with type 1 diabetes. . . . → Read More: Engineered Insulin-Producing Cells to Be Grown in Lab